Home » Newsletters » BioWorld

BioWorld

Feb. 10, 1993

View Archived Issues

HOLLINGS RENTON MOVES TO ONYX

CYTOGEN GAINS CANCER MAB LICENSE

EPIGEN FILES BROAD PATENT ON CARCINOMA ANTIGEN

IMCLONE STARTS CANCER VACCINE TRIALS

REGENERON'S SECOND CNTF PATENT ALLOWED

HOFFMAN-LAROCHE FACES AIDS ACTIVISTS

PROCYTE COMPLETES OFFERING

MACROCHEM NETS $6.3 MILLION IN PRIVATE PLACEMENT

EMISPHERE OFFERING TO BEGIN TRADING

CEPHALON FILES SECONDARY

CELL GENESYS GETS $10M TO DEVELOP MAbs

BIOSYS TO BUY PHEROMONE FIRM

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 10, 2025.
Corestemchemon preps US BLA filing for stem cell ALS therapy
BioWorld
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol
BioWorld
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty
BioWorld
With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...